- Patricia Tai, MB, BS, DABR, FRCR, FRCPC
Patricia Tai, MB, BS, DABR, FRCR, FRCPC
- Clinical Oncologist
- Clinical Professor
- University of Saskatchewan
- Canada Department of Radiation Oncology
- Allan Blair Cancer Center
- Section Editors
- Robert S Stern, MD
Robert S Stern, MD
- Section Editor — Nonmelanoma Skin Cancer
- Professor of Dermatology
- Harvard Medical School
- June K Robinson, MD
June K Robinson, MD
- Section Editor — Nonmelanoma Skin Cancer
- Professor of Clinical Dermatology
- Northwestern University Feinberg School of Medicine
Sebaceous carcinoma is a rare malignant tumor of the sebaceous glands . It can occur in any body site where sebaceous glands are present, but is most commonly found in the head and neck region, particularly in the periocular area . Sebaceous carcinoma of the eyelid (picture 1) may be mistaken for inflammatory lesions, such as chalazion or blepharoconjunctivitis, resulting in a delayed diagnosis and poorer prognosis .
Sebaceous carcinomas can occur sporadically or may be associated with Muir-Torre syndrome, a subset of the hereditary nonpolyposis colorectal cancer syndrome (HNCCS, Lynch syndrome) characterized by single or multiple sebaceous neoplasms, keratoacanthomas, and internal malignancy .
This topic will review the pathogenesis, clinical presentation, diagnosis, and treatment of sebaceous carcinoma. Muir-Torre syndrome and Lynch syndrome are discussed separately. (See "Muir-Torre syndrome" and "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis" and "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management".)
Sebaceous carcinoma is a rare tumor, with an estimated incidence rate of approximately 1 to 2 per 1,000,000 per year [2,4,5]. However, sebaceous carcinoma is the most common eyelid malignancy after basal cell carcinoma and squamous cell carcinoma [6,7].
A review of the Surveillance, Epidemiology and End Results (SEER) database from 1973 to 2004 identified 1349 cases of sebaceous carcinoma . More than 90 percent of cases were seen in patients over 50 years old and the median age was 72 years. Sebaceous carcinoma is exceedingly rare in children [8,9].
- Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg 2015; 41:1.
- Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 2009; 115:158.
- Muqit MM, Foot B, Walters SJ, et al. Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol 2013; 97:47.
- Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 2008; 113:3372.
- Kuzel P, Metelitsa AI, Dover DC, Salopek TG. Epidemiology of sebaceous carcinoma in Alberta, Canada, from 1988 to 2007. J Cutan Med Surg 2012; 16:417.
- Jakobiec FA, Mendoza PR. Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin. Am J Ophthalmol 2014; 157:186.
- Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol 2009; 31:256.
- Mebazaa A, Boussofara L, Trabelsi A, et al. Undifferentiated sebaceous carcinoma: an unusual childhood cancer. Pediatr Dermatol 2007; 24:501.
- Omura NE, Collison DW, Perry AE, Myers LM. Sebaceous carcinoma in children. J Am Acad Dermatol 2002; 47:950.
- Izumi M, Tang X, Chiu CS, et al. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J Dermatol 2008; 35:704.
- Ishida M, Iwai M, Yoshida K, et al. Sebaceous carcinoma associated with Bowen's disease: a case report with emphasis on the pathogenesis of sebaceous carcinoma. Int J Clin Exp Pathol 2013; 6:3029.
- Ishida M, Okabe H. Intraepidermal sebaceous carcinoma occurring concurrently with actinic keratosis. J Cutan Pathol 2012; 39:731.
- Nakashima K, Adachi K, Yamasaki A, et al. Sebaceous carcinoma with actinic keratosis. Acta Derm Venereol 2010; 90:196.
- Kraft S, Granter SR. Molecular pathology of skin neoplasms of the head and neck. Arch Pathol Lab Med 2014; 138:759.
- Harwood CA, Swale VJ, Bataille VA, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001; 116:246.
- Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol 2011; 65:1054.
- Rajan Kd A, Burris C, Iliff N, et al. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol 2014; 157:640.
- Shalin SC, Sakharpe A, Lyle S, et al. p53 staining correlates with tumor type and location in sebaceous neoplasms. Am J Dermatopathol 2012; 34:129.
- Hussain RM, Matthews JL, Dubovy SR, et al. UV-independent p53 mutations in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg 2014; 30:392.
- Jayaraj P, Sen S, Sharma A, et al. Eyelid sebaceous carcinoma: a novel mutation in lymphoid enhancer-binding factor-1. Br J Dermatol 2015; 173:811.
- Liau JY, Liao SL, Hsiao CH, et al. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. Hum Pathol 2014; 45:533.
- Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 2004; 111:2151.
- Shields JA, Demirci H, Marr BP, et al. Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg 2005; 21:92.
- Kumabe A, Kawase T, Miura K, et al. Sebaceous carcinoma of the parotid gland: F-18 FDG PET/CT findings. Clin Nucl Med 2010; 35:260.
- Gnepp DR. My journey into the world of salivary gland sebaceous neoplasms. Head Neck Pathol 2012; 6:101.
- Sawyer AR, McGoldrick RB, Mackey S, et al. Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy? Dermatol Surg 2009; 35:704.
- Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol 2008; 47:276.
- Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005; 103:1018.
- Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol 2007; 13:301.
- Mulay K, White VA, Shah SJ, Honavar SG. Sebaceous carcinoma: clinicopathologic features and diagnostic role of immunohistochemistry (including androgen receptor). Can J Ophthalmol 2014; 49:326.
- Ansai S, Takeichi H, Arase S, et al. Sebaceous carcinoma: an immunohistochemical reappraisal. Am J Dermatopathol 2011; 33:579.
- Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol 2009; 36:613.
- Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology 2010; 56:133.
- Edge SF, Byrd DR, Compton CC, et al. AJCC cancer staging manual, 7th ed, Springer, New York 2010.
- http://www.cancer.net/cancer-types/eyelid-cancer/stages-and-grades (Accessed on December 12, 2014).
- Hou JL, Killian JM, Baum CL, et al. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg 2014; 40:241.
- Callahan EF, Appert DL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg 2004; 30:1164.
- Snow SN, Larson PO, Lucarelli MJ, et al. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg 2002; 28:623.
- Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol 2001; 44:1004.
- Azad S, Choudhary V. Treatment results of high dose rate interstitial brachytherapy in carcinoma of eye lid. J Cancer Res Ther 2011; 7:157.
- Hata M, Koike I, Maegawa J, et al. Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function. Strahlenther Onkol 2012; 188:1102.
- Pardo FS, Wang CC, Albert D, Stracher MA. Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1989; 17:643.
- Lisman RD, Jakobiec FA, Small P. Sebaceous carcinoma of the eyelids. The role of adjunctive cryotherapy in the management of conjunctival pagetoid spread. Ophthalmology 1989; 96:1021.
- Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 2010; 94:1316.
- Tumuluri K, Kourt G, Martin P. Mitomycin C in sebaceous gland carcinoma with pagetoid spread. Br J Ophthalmol 2004; 88:718.
- Shields CL, Naseripour M, Shields JA, Eagle RC Jr. Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology 2002; 109:2129.
- Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006; 90:819.
- Deo SV, Shukla NK, Singh M, et al. Locally advanced sebaceous cell carcinoma (T3) of eyelid: incidence and pattern of nodal metastases and combined modality management approach. Orbit 2012; 31:150.
- Jung YH, Woo IS, Kim MY, et al. Palliative 5-fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: Case report and literature review. Asia Pac J Clin Oncol 2016; 12:e189.
- Orcurto A, Gay BE, Sozzi WJ, et al. Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy. Case Rep Dermatol 2014; 6:80.
- Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional nodal recurrence of sebaceous carcinoma of the caruncle 11 years after primary tumor resection. JAMA Ophthalmol 2013; 131:1091.
- Rath S, Honavar SG, Reddy VA, et al. Sebaceous carcinoma of the eyelid metastasizing to the lacrimal sac after 5 years. Orbit 2009; 28:309.
- Murthy R, Honavar SG, Burman S, et al. Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg 2005; 21:307.
- Priyadarshini O, Biswas G, Biswas S, et al. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg 2010; 26:366.
- Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: part I. J Am Acad Dermatol 2009; 61:549.
- Watanabe A, Sun MT, Pirbhai A, et al. Sebaceous carcinoma in Japanese patients: clinical presentation, staging and outcomes. Br J Ophthalmol 2013; 97:1459.
- Thomas WW, Fritsch VA, Lentsch EJ. Population-based analysis of prognostic indicators in sebaceous carcinoma of the head and neck. Laryngoscope 2013; 123:2165.
- CLINICAL PRESENTATION
- Eyelid sebaceous carcinoma
- Extra-ocular sebaceous carcinoma
- ASSOCIATION WITH MUIR-TORRE SYNDROME
- Screening for DNA mismatch repair defects
- DIFFERENTIAL DIAGNOSIS
- EVALUATION AND STAGING
- Local disease
- - Surgical treatment
- - Radiation therapy
- - Adjuvant therapies
- Metastatic disease
- SUMMARY AND RECOMMENDATIONS